...
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin
【24h】

Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin

机译:癌症患者尿肾衰竭生物标志物的差异最初用顺铂治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Background/Aim: We investigated whether measuring the excretion of each acute kidney injury (AKI) biomarker after cisplatin (CDDP) administration is useful for predicting AKI and evaluated the most appropriate AKI marker in patients treated with CDDP. Patients and Methods: We measured NAG, Kim-1, and NGAL in urinary samples of 40 cancer patients treated with chemotherapy on day 1 (before chemotherapy), day 2, and day 5 after treatment; serum creatinine (sCr) was compared on days 7 and 28 after CDDP administration vs. baseline. Results: NAG, Kim-1, and NGAL excretion (creatinine corrected) were not significantly elevated 5 days after receiving chemotherapy in the non-CDDP chemotherapy group. Conversely, all markers were significantly higher 5 days after receiving chemotherapy in the CDDP group when compared to baseline. Conclusion: Urinary NAG, Kim-1, and NGAL can detect renal injury more sensitively than sCr.
机译:背景/目的:我们调查了在顺铂(CDDP)给药后测量每种急性肾损伤(AKI)生物标志物的排泄可用于预测AKI并评估用CDDP治疗的患者中最合适的AKI标志物。 患者和方法:在治疗后第1天(化疗前),第2天和第5天治疗的40名癌症患者的尿样,测量NAG,KIM-1和NGAL尿液样本中的尿液样本; 在CDDP给药施用后的第7天和第28天比较血清肌酐(SCR)。 结果:在非CDDP化疗组中接受化疗后,NAG,KIM-1和NGAL排泄(肌酐校正)在接受化疗后5天并没有显着升高。 相反,当与基线相比,在CDDP组中接受化疗后,所有标记均明显更高。 结论:尿纳格,Kim-1和Ngal可以比SCR更敏感地检测肾损伤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号